Dinutuximab Combination Therapy Becomes First Approval for High-Risk Neuroblastoma

Journal of Community and Supportive Oncology - United States
doi 10.12788/jcso.0172
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontline Medical Communications, Inc.